1. Long-term disease-free survival after MIBG therapy for metastatic pheochromocytoma.
- Author
-
John JR, Hephzibah J, Shanthly N, and Oommen R
- Subjects
- Humans, Female, Adult, Disease-Free Survival, Iodine Radioisotopes therapeutic use, Bone Neoplasms secondary, Bone Neoplasms radiotherapy, Radionuclide Imaging, Pheochromocytoma, 3-Iodobenzylguanidine therapeutic use, Adrenal Gland Neoplasms secondary, Radiopharmaceuticals therapeutic use
- Abstract
Pheochromocytomas are rare tumours originating in chromaffin cells, representing 0.1%-1% of all secondary hypertension cases. The majority are benign and unilateral, characterised by the production of catecholamines and other neuropeptides. Mainly located in the adrenal gland, they are more frequent between the third and fifth decades of life. Iodine-131 metaiodobenzylguanidine (
131 I-MIBG), a radiopharmaceutical agent used for scintigraphic localisation of pheochromocytomas, has been employed to treat malignant pheochromocytomas since 1983 in a few specialised centres around the world. We reviewed our clinical experience in one such case of a young lady who presented with history of abdominal pain, headache and lower back pain. On evaluation, ultrasonography revealed a right adrenal mass and elevated urine vanillylmandelic acid levels. Following surgical resection and histopathological confirmation of pheochromocytoma, MIBG scintigraphy revealed osseous metastases and hence, she underwent131 I-MIBG therapy., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2024
- Full Text
- View/download PDF